Show Navigation

Image 1 of 1

ALZHEIMER BLOOD 05.jpg

ST. LOUIS - Sept. 9, 2022: Samantha Koch, a biotechnology laboratory scientist at C2N Diagnostics, demonstrates how the molecular diagnostics company processes plasma as part of detecting biomarkers of Alzheimer’s disease. at a laboratory in St. Louis Friday, Sept. 9, 2022. The firm’s blood test uses an in vitro diagnostic laboratory-developed test for brain amyloid detection, a pathologic hallmark of Alzheimer’s disease. (Photo by Sid Hastings/For The Washington Post)
Copyright
© Sid Hastings
Image Size
6000x3992 / 12.4MB
https://www.sidhastings.com/p/image-license-or-pur
https://www.sidhastings.com/contact
Contained in galleries
ST. LOUIS - Sept. 9, 2022: Samantha Koch, a biotechnology laboratory scientist at C2N Diagnostics, demonstrates how the molecular diagnostics company processes plasma as part of detecting biomarkers of Alzheimer’s disease. at a laboratory in St. Louis Friday, Sept. 9, 2022. The firm’s blood test uses an in vitro diagnostic laboratory-developed test for brain amyloid detection, a pathologic hallmark of Alzheimer’s disease. (Photo by Sid Hastings/For The Washington Post)